Join to View Full Profile
44 Binney StreetDana Farber Cancer InstituteBoston, MA 02115
Phone+1 617-632-2334
Fax+1 617-632-3479
Dr. Butler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 2000
Johns Hopkins UniversityResidency, Internal Medicine, 1992 - 1995
Yale School of MedicineClass of 1992
Certifications & Licensure
MA State Medical License 1995 - 2012
Clinical Trials
- Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma Start of enrollment: 2007 Aug 01
- Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
Roles: Contact, Principal Investigator
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. Start of enrollment: 2022 May 02
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients With BRAF V600-Mutant Metastatic Melanoma.Reinhard Dummer, Shahneen Sandhu, Wilson H Miller, Marcus O Butler, Matthew H Taylor
Clinical Cancer Research. 2025-03-19 - Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINAT...Adi Diab, Paolo A Ascierto, Michele Maio, Reham Abdel-Wahab, Sylvie Negrier
Journal of Clinical Oncology. 2025-03-06 - Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies.Juanita S Lopez, Mohammed Milhem, Marcus O Butler, Fiona Thistlethwaite, Brian A Van Tine
Cell Reports. Medicine. 2025-02-27
Press Mentions
Accuracy of Skin Cancer Diagnosis Varies by Physician, Exam MethodNovember 14th, 2024- Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal MelanomaJune 8th, 2022
- Asthma Society’s Pollen Tacker Predicts High Pollen Levels This WeekendJuly 14th, 2020
- Join now to see all
Grant Support
- Detection Of Immunogenic Ovarian Cancer AntigensNational Cancer Institute2000–2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
